Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib

Jacob Mentzel,Laura S. Hildebrand,Lukas Kuhlmann,Rainer Fietkau,Luitpold V. Distel

DOI: https://doi.org/10.3390/ijms25115629

IF: 5.6

2024-05-23

International Journal of Molecular Sciences

Abstract:(1) Head and neck squamous cell carcinoma (HNSCC) is common, while treatment is difficult, and mortality is high. Kinase inhibitors are promising to enhance the effects of radiotherapy. We compared the effects of the PARP inhibitors talazoparib and niraparib and that of the DNA-PKcs inhibitor AZD7648, combined with ionizing radiation. (2) Seven HNSCC cell lines, including Cal33, CLS-354, Detroit 562, HSC4, RPMI2650 (HPV-negative), UD-SCC-2 and UM-SCC-47 (HPV-positive), and two healthy fibroblast cell lines, SBLF8 and SBLF9, were studied. Flow cytometry was used to analyze apoptosis and necrosis induction (AnnexinV/7AAD) and cell cycle distribution (Hoechst). Cell inactivation was studied by the colony-forming assay. (3) AZD7648 had the strongest effects, radiosensitizing all HNSCC cell lines, almost always in a supra-additive manner. Talazoparib and niraparib were effective in both HPV-positive cell lines but only consistently in one and two HPV-negative cell lines, respectively. Healthy fibroblasts were not affected by any combined treatment in apoptosis and necrosis induction or G2/M-phase arrest. AZD7648 alone was not toxic to healthy fibroblasts, while the combination with ionizing radiation reduced clonogenicity. (4) In conclusion, talazoparib, niraparib and, most potently, AZD7648 could improve radiation therapy in HNSCC. Healthy fibroblasts tolerated AZD7648 alone extremely well, but irradiation-induced effects might occur. Our results justify in vivo studies.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to improve the sensitivity of head and neck squamous cell carcinoma (HNSCC) to radiotherapy. Specifically, the researchers explored enhancing the sensitivity of HNSCC cell lines to radiotherapy by using the DNA - PKcs inhibitor AZD7648 and the PARP inhibitors talazoparib and niraparib. ### Research Background 1. **The Current Situation and Challenges of HNSCC**: - HNSCC is the eighth most common cancer worldwide, with more than 878,000 new cases and more than 444,000 deaths each year. - The 5 - year survival rate is approximately 50%, ranging from 80% in stage I to 20% in stage III/IV. - Late - stage diagnosis is closely related to low survival rates, and there are currently no effective screening strategies. - The main risk factors include smoking, drinking, environmental pollution, chewing betel nuts, and infection with EBV and HPV viruses. 2. **The Importance of Radiotherapy**: - Radiotherapy plays an important role in the treatment of HNSCC, but some types of HNSCC (especially HPV - negative ones) are more resistant to radiotherapy, resulting in a poor prognosis. 3. **The Mechanism of Radiosensitization**: - Radiation induces DNA damage, including single - strand breaks (SSBs) and double - strand breaks (DSBs). DSBs are the most lethal DNA damage, and if not repaired, they can lead to cell - cycle arrest or cell death. - Inhibiting the DNA damage repair system (DDR), especially non - homologous end - joining (NHEJ) and single - strand break repair systems, can increase the radiosensitization effect. ### Research Objectives This study aims to evaluate whether the PARP inhibitors talazoparib and niraparib, as well as the highly selective DNA - PKcs inhibitor AZD7648, can enhance the sensitivity of HNSCC cell lines to radiotherapy in vitro. Specific objectives include: - **Evaluating the Responses of Different Cell Lines**: To study the responses of seven HNSCC cell lines (two of which are HPV - positive and five are HPV - negative) and two healthy fibroblast cell lines to the combined treatment of these inhibitors and radiation. - **Analyzing Cell Death and Cell - Cycle Arrest**: To analyze apoptosis, necrosis, and G2/M - phase arrest by flow cytometry. - **Evaluating Long - Term Proliferation Ability**: To evaluate the long - term proliferation ability of cells by clonogenic assay. ### Research Conclusions The research results show that AZD7648 exhibits the strongest radiosensitization effect in all HNSCC cell lines, usually enhanced in a supra - additive manner. Talazoparib and niraparib also show certain radiosensitization effects in HPV - positive and some HPV - negative cell lines. Healthy fibroblasts are more tolerant to these treatments, but may still have certain side effects when combined with radiation. In conclusion, this study provides important experimental evidence for improving HNSCC radiotherapy in the future and suggests that further in - vivo studies are necessary.

Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib

The Combination of Icotinib Hydrochloride and Fluzoparib Enhances the Radiosensitivity of Biliary Tract Cancer Cells

Data from Integrative Analysis Identifies a Novel AXL–PI3 Kinase–PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer

Different Impacts of DNA-PK and mTOR Kinase Inhibitors in Combination with Ionizing Radiation on HNSCC and Normal Tissue Cells

Inhibition of key DNA double strand break repair protein kinases enhances radiosensitivity of head and neck cancer cells to X-ray and proton irradiation

DNA-PK inhibitor AZD7648 is a more portent radiosensitizer than PARP inhibitor Olaparib in BRCA1/2 deficient tumors

Synthesis of a new class of camptothecin derivatives, the long-chain fatty acid esters of 10-hydroxycamptothecin, as a potent prodrug candidate, and their in vitro metabolic conversion by carboxylesterases.

HPV and p53 status as precision determinants of head and neck cancer response to DNA-PKcs inhibition in combination with irradiation

Enhanced efficacy of combined fluzoparib and chidamide targeting in natural killer/T-cell lymphoma

Phase II study evaluating the efficacy of niraparib and dostarlimab (TSR-042) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) patients.

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade

DNA-PKcs Inhibition Sensitizes Human Chondrosarcoma Cells to Carbon Ion Irradiation via Cell Cycle Arrest and Telomere Capping Disruption

A phase II study of niraparib and dostarlimab with radiation in patients with metastatic pancreatic cancer.

The Emerging Role of Poly (ADP-Ribose) Polymerase Inhibitors as Effective Therapeutic Agents in Renal Cell Carcinoma

Combining [177Lu]Lu-DOTA-TOC PRRT with PARP inhibitors to enhance treatment efficacy in small cell lung cancer

Abstract 7130: Dysregulated DNA repaired elicited by type 1 PRMT inhibitor in clear cell renal cell carcinoma enables development of novel combination therapies

Abstract 701: Preclinical data of a novel DNA-PK inhibitor in combination with radiation therapy shows promise in the treatment of established GBM and lung carcinoma cell lines

The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects

Radiotherapy and the cellular DNA damage response: current and future perspectives on head and neck cancer treatment

Sympathetic neural activity to the cardiovascular system: integrator of systemic physiology and interindividual characteristics.